12:00 AM
 | 
Nov 25, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Isavuconazole regulatory update

Basilea said FDA granted Orphan Drug designation to isavuconazole to treat zygomycosis. The broad spectrum water-soluble azole antifungal is in preclinical testing for the indication. It is also in the Phase III VITAL trial to treat...

Read the full 158 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >